Correction to: Hyperkalemia in heart failure with reduced ejection fraction: implications and management

In the originally published version of this article, errors were identified in the reference list, and the authors’ conflicts of interest statements that were submitted with the accepted manuscript were inadvertently omitted from the final published version.

These issues are limited to the reference list and disclosure statements only and do not affect the data, interpretation, or conclusions of the article.

Conflict of interest disclosure statements

The authors’ conflicts of interest statements, as originally submitted with the accepted manuscript, were not included in the published article. The full, correct conflicts of interest statements are reproduced below:

Dr. Beavers: Dr. Beavers reports consultant fees from Bayer. Dr. Greene: Dr Greene has received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Otsuka, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Idorsia, Lexicon, Lilly, Merck, Mineralys, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo, Tricog Health, and Viatris.

Reference corrections

Several references contained inaccuracies in citation details. The corrected versions of the affected references are provided below: